Guest Post: A Relentless Focus on the Given – Reviewing O. Carter Snead’s What it Means to be Human: The Case for the Body in Public Bioethics

Guest Post by Charles Camosy

Professor Carter Snead, at least in my world, is about as important a contemporary voice in bioethics that we have today. A professor on Notre Dame’s law faculty, he is perhaps better known as director of the de Nicola Center for Ethics and Culture—one of the most significant positions in the United States for doing public bioethics. He was heavily involved in the topic before coming to Notre Dame, including when serving as general counsel to the President’s Council on Bioethics chaired by Leon Kass. He currently serves on the Pontifical Academy for Life and as an elected fellow of the Hastings Center.

When Professor Snead came out with a book on public bioethics from Harvard University Press this month, that became good reason for many of us to pay close attention—especially when Alasdair MacIntyre gave a back cover endorsement calling it “indispensable reading” whether “you agree or disagree with Snead’s perspective.” Indeed, Snead makes it clear that he’s not merely preaching to the choir in this book, but instead aiming at making his case to folks with  different perspectives in “the spirit of friendship” and “anchored in the firm belief that we can only govern ourselves wisely, humanly, and justly if we become the kind of people who can make each other’s goods our own.” Continue reading

An Ambitious Vision for Bioethics – Some Reflections on Professor Jing-Bao Nie’s St Cross Seminar

Written by Ben Davies

Many readers of the Practical Ethics blog will remember the astounding announcement last November by Chinese researcher He Jiankui that he had used CRISPR-cas9 technology to edit into two healthy embryos a resistance to developing HIV, later resulting in the birth of twins Lulu and Nana. As Professor Julian Savulescu expressed in several posts on this blog, the announcement spurred widespread ethical condemnation.

The first in this year’s series of St Cross Special Ethics seminars saw the University of Otago’s Professor Jing-Bao Nie (who is also currently a 2019/20 Fellow of Durham University’s Institute of Advanced Study) get behind the headlines to consider the political and social context of He’s experiment. At the core of Professor Nie’s presentation was that the decision to engage in genetic editing of healthy embryos could neither be written off as the act of a ‘rogue researcher’, nor dismissed as merely the product of a uniquely Chinese disregard for ethics, as some have argued.

Continue reading

Human In Vitro Gametogenesis and the Same-Sex Marriage Debate

Written by César Palacios-González

It seems that in the not-so-distant future, scientists will be able to create functional human gametes (i.e. eggs and sperm) in a laboratory setting. In other words, they will be able to create human gametes outside of the human body. And just as there is in vitro fertilization (IVF), there will be in vitro gametogenesis (IVG). This means that our already long list of human reproductive acronyms –IVF, PGD, ICSI, PNT, PBT1, PBT2, MST, UTx, CT, etc.–  will get a bit longer. At present, some of the best biology labs from around the world are actively working on how to achieve such goal, and non-human animal models have shown some amazing results.

For starters, scientists have successfully derived in a laboratory setting mouse oocyte-like cells and sperm-like cells from induced pluripotent stem cells and embryonic stem cells. And, most surprisingly, they have been able to create what has been called “cross-sex gametes”. This means that they have been able to create sperm-like cells from female mice, and oocyte-like cells from male mice (I use the terms ‘sperm-like’ and ‘oocyte-like’ because these cells are not identical to naturally occurring gametes). Some of such cross-sex gametes have, in turn, been capable of producing live offspring. Continue reading

Genome editing – the key ethical issues

Written by Dr Christopher Gyngell

This article originally appeared on the OMS website

The Nuffield Council of Bioethics released a report last Friday outlining the key ethical issues raised by genome editing technologies.

Genome editing (GE) is a powerful, and extremely rapidly developing technology. It uses engineered enzymes to make precise, controlled modification to DNA. It has the potential to radically transform many industries, including medicine, agriculture and ecology.  Despite only being developed in the past few years’, GE has already been used to create malaria-fighting mosquitoes, drought resistant wheat, hornless cows and cancer killing immune cells. The potential applications of GE in a decade are difficult to imagine. It raises a wide range of ethical issues that require careful scrutiny. Continue reading

“The medicalization of love” – podcast interview

Just out today is a podcast interview for Smart Drug Smarts between host Jesse Lawler and interviewee Brian D. Earp on “The Medicalization of Love” (title taken from a recent paper with Anders Sandberg and Julian Savulescu, available from the Cambridge Quarterly of Healthcare Ethics, here).

Below is the abstract and link to the interview:


What is love? A loaded question with the potential to lead us down multiple rabbit holes (and, if you grew up in the 90s, evoke memories of the Haddaway song). In episode #95, Jesse welcomes Brian D. Earp on board for a thought-provoking conversation about the possibilities and ethics of making biochemical tweaks to this most celebrated of human emotions. With a topic like “manipulating love,” the discussion moves between the realms of neuroscience, psychology and transhumanist philosophy. 


Earp, B. D., Sandberg, A., & Savulescu, J. (2015). The medicalization of love. Cambridge Quarterly of Healthcare Ethics, Vol. 24, No. 3, 323–336.

Pinker Bioethics: What Should We Learn?

Julian Savulescu 
Twitter @juliansavulescu

Steven Pinker has recently written an op-ed questioning the contribution of bioethics to the safe and efficient regulation of research. This has been widely misinterpreted and criticised, though Alice Dreger has written a recent accurate blog in support of Pinker. Pinker provocatively said that bioethics should get out of the way of research. This has been interpreted to mean that we should give up ethics review of research. Nobody, not me, and not Steven Pinker, thinks we should abandon ethical review of research. He actually says, ” Of course, individuals must be protected from identifiable harm, but we already have ample safeguards for the safety and informed consent of patients and research subjects.” Pinker is objecting to the unnecessary, unproductive obstruction that much bioethics represents to good research and regulation.

I largely agree with him and have said as much myself over the years. I recently wrote a piece for the anniversary issue of the JME arguing as much. I applaud him for trying to generate some self-reflection in the field.

Continue reading

Guest Post: The Moral Imperative for Bioethics

By Daniel K. Sokol
Daniel Sokol, PhD, is a bioethicist and lawyer at 12 King’s Bench Walk, London. He has sat on several ethics committees, including the UK’s Ministry of Defence’s Research Ethics Committee.

In a recent Opinion piece in the Boston Globe, Professor Steven Pinker made the surprising suggestion that the primary moral goal of today’s bioethics should be to “get out of the way”. “A truly ethical bioethics”, he argued, “should not bog down research in red tape, moratoria or threats of prosecution”.

This bold assertion no doubt echoes the thoughts of many scientists whose research requires the approval of an ethics review committee before springing to life. As a PhD student many years ago, I experienced first hand the frustrations of the tedious review process. I spent hours drafting the protocol, revisions and responding to the Committee’s questions, time I would have preferred to spend conducting research. While a popular sentiment, getting out of the way is not the goal of bioethics.

The goal of bioethics is to allow potentially beneficial research while ensuring that the risk of harm to participants and others is proportionate, reduced to the lowest practicable level, and within morally acceptable limits. The risk of harm can never be eliminated, but it can usually be reduced with minimal effort or cost. It may be as simple as testing a new piece of equipment one more time in a laboratory before attaching it to a human for testing.

Continue reading

What are the ethics of using brain stimulation technologies for ‘enhancement’ in children?

New open access publication: announcement:

In a recently published article, Hannah Maslen, Roi Cohen Kadosh, Julian Savulescu and I present an argument about the permissible (and not-so-permissible) uses of non-invasive brain stimulation technology in children. We consider both children who may be suffering from a specific neurological disorder, for whom the stimulation is intended as a ‘treatment’, and those who are otherwise healthy, for whom the stimulation is intended as ‘enhancement’. For the full article and citation, see here:

Maslen, H., Earp, B. D., Cohen Kadosh, R., & Savulescu, J. (2014). Brain stimulation for treatment and enhancement in children: An ethical analysisFrontiers in Human Neuroscience, Vol. 8, Article 953, 1-5. Continue reading

Horizon 2020 and The Role of Lay People’s Perspectives in Bioethical Reasoning

By Kimberly Schelle & Nadira Faulmüller

Horizon 2020, the European Union’s 2014-2020 largest research programme ever, includes the call to pursue ‘Responsible Research and Innovation’ (RRI). RRI stands for a research and innovation process in which all societal actors (e.g. citizens, policy makers, business and researchers) are working together in the process to align the outcomes with the values, needs, and expectations of the European Society. In a recently published paper on the importance of including the public and patients’ voices in bioethical reasoning, the authors describe, although in other words, the value of the RRI approach in bioethical issues:

“A bioethical position that fails to do this [exchange with the public opinion], and which thus avoids the confrontation with different public arguments, including ones perhaps based in different cultural histories, relations and ontological grounds […], not only runs the risk of missing important aspects, ideas and arguments. It also arouses strong suspicion of being indeed one-sided, biased or ideological—thus illegitimate.”

Continue reading

“The Medicalization of Love” – call for peer commentaries – DUE SEPT 1


The paper, “The Medicalization of Love” by Brian D. Earp, Anders Sandberg, and Julian Savulescu, has been accepted for publication at the Cambridge Quarterly of Healthcare Ethics. Scholars interested in submitting a short reply paper or peer commentary are encouraged to contact the editor, Tomi Kushner, at

The final deadline for commentaries/ papers is September 1st. The abstract for the paper is below; the accepted manuscript is available at this link. Inquiries to the editor should be sent as soon as possible.


Pharmaceuticals or other emerging technologies could be used to enhance (or diminish) feelings of lust, attraction, and attachment in adult romantic partnerships. While such interventions could conceivably be used to promote individual (and couple) well-being, their widespread development and/or adoption might lead to “medicalization” of human love and heartache—for some, a source of serious concern. In this essay, we argue that the “medicalization of love” need not necessarily be problematic, on balance, but could plausibly be expected to have either good or bad consequences depending upon how it unfolds. By anticipating some of the specific ways in which these technologies could yield unwanted outcomes, bioethicists and others can help direct the course of love’s “medicalization”—should it happen to occur—more toward the “good” side than the “bad.”

Here is the link to the accepted manuscript.

* image from